Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Snapchat

Mtech Access certified as a NICE META tool facilitating organisation

Mtech Access are now a certified NICE META Tool facilitating organisation, with three experts having passed the NICE assessment

Mtech Access

- PMLiVE

New £5m project launched to bring Alzheimer’s blood tests to the NHS

Blood tests for the condition could become available on the NHS within five years

- PMLiVE

UK antibiotic subscription model found by OHE as key to supporting investment

The OHE report offers valuable insights into investor views of the subscription model

- PMLiVE

The Power of Disease Awareness in Infectious Disease Education at IDWeek 2023

Medscape Education had one of its biggest conferences of the year with IDWeek 2023, hosting six educational symposia and presenting five scientific posters highlighting the outcomes of recent infectious disease...

Medscape Education Global

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

Contagious Conversations: Exploring Infectious Disease in the Digital Age

As the world of medicine continues to evolve, it's crucial to stay ahead of the curve. In this dynamic era, digital communications have emerged as a driving force in discussions...

Medscape Education Global

- PMLiVE

Bristol Myers Squibb’s Sotyktu recommended by NICE for plaque psoriasis

An estimated 1.8 million people in the UK are affected by some form of the condition

The Evolving Role of Social Media in Healthcare

In recent years, social media has evolved into an essential part of Pharma operations, for better or worse.

Impetus Digital

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer

The treatment has been recommended for use within a managed access arrangement

- PMLiVE

Boehringer Ingelheim’s idiopathic pulmonary fibrosis treatment recommended by NICE

Patients will be eligible for the antifibrotic treatment earlier in the course of their disease

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links